Declining HCV seroprevalence in pregnant women with HIV

Autor: Floridia M., Tamburrini E., Anzidei G., Tibaldi C., M. L. Muggiasca M. L., Guaraldi G., Fiscon M., Vimercati A, Martinelli P., Donisi A., Dalzero S., Ravizza M., the italian Group on Surveillance on Antiretroviral Treatment in Pregnancy [, GUERRA, BRUNELLA
Přispěvatelé: Floridia M., Tamburrini E., Anzidei G., Tibaldi C., M. L. Muggiasca M. L., Guaraldi G., Fiscon M., Vimercati A, Martinelli P., Donisi A., Dalzero S., Ravizza M., the italian Group on Surveillance on Antiretroviral Treatment in Pregnancy [, Guerra B., ], Floridia, M, Tamburrini, E, Anzidei, G, Tibaldi, C, Muggiasca, Ml, Guaraldi, G, Fiscon, M, Vimercati, A, Martinelli, Pasquale, Donisi, A, Dalzero, S, Ravizza, M, for the Italian Group on Surveillance on Antiretroviral Treatment in, Pregnancy
Rok vydání: 2010
Předmět:
Zdroj: Epidemiology and infection. 138(9)
ISSN: 1469-4409
Popis: SUMMARYWe assessed recent trends in hepatitis C virus (HCV) prevalence in pregnant women with HIV using data from a large national study. Based on 1240 pregnancies, we observed a 3·4-fold decline in HCV seroprevalence in pregnant women with HIV between 2001 (29·3%) and 2008 (8·6%). This decline was the net result of two components: a progressively declining HCV seroprevalence in non-African women (from 35·7% in 2001 to 16·7% in 2008), sustained by a parallel reduction in history of injecting drug use (IDU) in this population, and a significantly growing presence (from 21·2% in 2001 to 48·6% in 2008) of women of African origin, at very low risk of being HCV-infected [average HCV prevalence 1%, adjusted odds ratio (aOR) for HCV 0·09, 95% CI 0·03–0·29]. Previous IDU was the stronger determinant of HCV co-infection in pregnant women with HIV (aOR 30·9, 95% CI 18·8–51·1). The observed trend is expected to translate into a reduced number of cases of vertical HCV transmission.
Databáze: OpenAIRE